George Clinical welcomes Kristina Figueroa and Mindy Farr to the George Clinical team

George Clinical is pleased to announce the continued expansion of their Business Development operations in the US, with the recent appointments of Mindy Farr as Senior Business Development Manager and Kristina Figueroa, Business Development Manager. “Both Mindy and Kristina are joining George Clinical at an exciting time in the organisation’s history”, Mr Clark said. “We […]

Read More

The George Institute – Winners of the Google Impact Challenge

Video Transcript Congratulations on The Google Impact Challenge win. Can you explain what TEXTCARE does and what issue it addresses? 0:07 – 3:09 It is really exciting; I think we’re all a little bit stunned still, although I feel that we did have a fabulous proposal and it’s very exciting to think that we will […]

Read More

Wearables are Improving Clinical Trial Research

The face of individual health care is changing and improving, thanks to wearables. Wearable health and fitness devices are becoming more popular by the day and with our mobile devices and wearables prompting us to keep up with good health habits, overall health is improving too. As individuals are more aware of their health, more […]

Read More

Which clinical trials need a Clinical Endpoint Adjudication Committee?

Increasingly, regulatory authorities are placing significant focus on clinical trial processes that ensure consistent, standardized, objective and unbiased reporting of safety and efficacy results; given that the definitions for many endpoint events include subjective components, and investigator-to-investigator subjective assessments may differ. Moreover, an increasing number of trials are now conducted in multiple geographies, and clinical […]

Read More

Why digital health is beneficial to clinical trials

In the world of healthcare, time is always of the essence. Researchers are continuously looking for new solutions to help improve patients’ well-being and ultimately save lives. The discovery process of new treatments takes an enormous amount of time and resources in order to generate good evidence to prove that they are safe and that […]

Read More

Thrombolysis will continue to be the mainstay for acute stroke treatment

Thrombolysis will continue to be the mainstay for acute stroke treatment, despite the recent revolution in neurointerventional clot retrieval. However, as there are ongoing limitations of thrombolysis of bleeding risk and reduced efficacy in large clots – what possible therapeutic advancements can complement or act as an adjuvant to thrombolysis? Neurointervention – effective, but limited […]

Read More

Regulatory timelines in the Asia-Pacific

An at-a-glance round-up of the arrangements for clinical trial applications in 10 countries in the region. Australia Australia is unique in that its Human Research Ethics Committees (HRECs) have responsibility for the oversight and ongoing monitoring of trials, including reviews and approvals. The first step is submission of the clinical trial to the HREC for […]

Read More

The Changing Role of the CRA in an RBM World

Approximately a third of clinical trials conducted utilize some elements of Risk Based Monitoring (RBM), with this figure expected to increase. Site monitoring has been identified as one of the largest components of clinical trial expenditure. With the change in the way that site monitoring is performed, the role of the Clinical Research Associate (CRA) […]

Read More

Twitter Facebook LinkedIn